Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1995 Nov;63(11):4211–4218. doi: 10.1128/iai.63.11.4211-4218.1995

Antibody immunity and invasive fungal infections.

A Casadevall 1
PMCID: PMC173598  PMID: 7591049

Full Text

The Full Text of this article is available as a PDF (232.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ammann A. J., Hong R. Selective IgA deficiency: presentation of 30 cases and a review of the literature. Medicine (Baltimore) 1971 May;50(3):223–236. [PubMed] [Google Scholar]
  2. Ashman R. B., Papadimitriou J. M. Strain dependence of antibody-mediated protection in murine systemic candidiasis. J Infect Dis. 1993 Aug;168(2):511–513. doi: 10.1093/infdis/168.2.511-a. [DOI] [PubMed] [Google Scholar]
  3. Balish E., Filutowicz H. Serum antibody response of gnotobiotic athymic and euthymic mice following alimentary tract colonization and infection with Candida albicans. Can J Microbiol. 1991 Mar;37(3):204–210. doi: 10.1139/m91-031. [DOI] [PubMed] [Google Scholar]
  4. Briles D. E., Forman C., Crain M. Mouse antibody to phosphocholine can protect mice from infection with mouse-virulent human isolates of Streptococcus pneumoniae. Infect Immun. 1992 May;60(5):1957–1962. doi: 10.1128/iai.60.5.1957-1962.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brueske C. H. Proteolytic activity of a clinical isolate of Cryptococcus neoformans. J Clin Microbiol. 1986 Mar;23(3):631–633. doi: 10.1128/jcm.23.3.631-633.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brummer E., Morozumi P. A., Vo P. T., Stevens D. A. Protection against pulmonary blastomycosis: adoptive transfer with T lymphocytes, but not serum, from resistant mice. Cell Immunol. 1982 Nov 1;73(2):349–359. doi: 10.1016/0008-8749(82)90461-0. [DOI] [PubMed] [Google Scholar]
  7. Brunham R. C., Plummer F. A., Stephens R. S. Bacterial antigenic variation, host immune response, and pathogen-host coevolution. Infect Immun. 1993 Jun;61(6):2273–2276. doi: 10.1128/iai.61.6.2273-2276.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Burges G., Holley H. P., Virella G. Circulating immune complexes in patients with Candida albicans infections. Clin Exp Immunol. 1983 Jul;53(1):165–174. [PMC free article] [PubMed] [Google Scholar]
  9. Böhler K., Klade H., Poitschek C., Reinthaller A. Immunohistochemical study of in vivo and in vitro IgA coating of candida species in vulvovaginal candidiasis. Genitourin Med. 1994 Jun;70(3):182–186. doi: 10.1136/sti.70.3.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Carrow E. W., Hector R. F., Domer J. E. Immunodeficient CBA/N mice respond effectively to Candida albicans. Clin Immunol Immunopathol. 1984 Dec;33(3):371–380. doi: 10.1016/0090-1229(84)90308-8. [DOI] [PubMed] [Google Scholar]
  11. Casadevall A., Mukherjee J., Devi S. J., Schneerson R., Robbins J. B., Scharff M. D. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis. 1992 Jun;165(6):1086–1093. doi: 10.1093/infdis/165.6.1086. [DOI] [PubMed] [Google Scholar]
  12. Casanova M., Martínez J. P., Chaffin W. L. Fab fragments from a monoclonal antibody against a germ tube mannoprotein block the yeast-to-mycelium transition in Candida albicans. Infect Immun. 1990 Nov;58(11):3810–3812. doi: 10.1128/iai.58.11.3810-3812.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cassone A., Boccanera M., Adriani D., Santoni G., De Bernardis F. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect Immun. 1995 Jul;63(7):2619–2624. doi: 10.1128/iai.63.7.2619-2624.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cates K. L., Grady P. G., Shapira E., Davis A. T. Cell-directed inhibition of polymorphonuclear leukocyte chemotaxis in a patient with mucocutaneous candidiasis. J Allergy Clin Immunol. 1980 Jun;65(6):430–435. doi: 10.1016/0091-6749(80)90235-3. [DOI] [PubMed] [Google Scholar]
  15. Chaffin W. L., Skudlarek J., Morrow K. J. Variable expression of a surface determinant during proliferation of Candida albicans. Infect Immun. 1988 Feb;56(2):302–309. doi: 10.1128/iai.56.2.302-309.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Cherniak R., Morris L. C., Belay T., Spitzer E. D., Casadevall A. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect Immun. 1995 May;63(5):1899–1905. doi: 10.1128/iai.63.5.1899-1905.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Cherniak R., Sundstrom J. B. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect Immun. 1994 May;62(5):1507–1512. doi: 10.1128/iai.62.5.1507-1512.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Chilgren R. A., Hong R., Quie P. G. Human serum interactions with Candida albicans. J Immunol. 1968 Jul;101(1):128–132. [PubMed] [Google Scholar]
  19. Collins H. L., Bancroft G. J. Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses. Infect Immun. 1991 Nov;59(11):3883–3888. doi: 10.1128/iai.59.11.3883-3888.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Coogan M. M., Sweet S. P., Challacombe S. J. Immunoglobulin A (IgA), IgA1, and IgA2 antibodies to Candida albicans in whole and parotid saliva in human immunodeficiency virus infection and AIDS. Infect Immun. 1994 Mar;62(3):892–896. doi: 10.1128/iai.62.3.892-896.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Costantino P. J., Franklyn K. M., Gare N. F., Warmington J. R. Production of antibodies to antigens of Candida albicans in CBA/H mice. Infect Immun. 1994 Apr;62(4):1400–1405. doi: 10.1128/iai.62.4.1400-1405.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Costantino P. J., Gare N. F., Warmington J. R. Humoral immune responses to systemic Candida albicans infection in inbred mouse strains. Immunol Cell Biol. 1995 Apr;73(2):125–133. doi: 10.1038/icb.1995.20. [DOI] [PubMed] [Google Scholar]
  23. Cox R. A., Pope R. M., Stevens D. A. Immune complexes in coccidioidomycosis. Correlation with disease involvement. Am Rev Respir Dis. 1982 Sep;126(3):439–443. doi: 10.1164/arrd.1982.126.3.439. [DOI] [PubMed] [Google Scholar]
  24. DROUHET E., SEGRETAIN G. Inhibition de la migration leucocytaire in vitro par un polyoside capsulaire de Torulopsis (Cryptococcus) neoformans. Ann Inst Pasteur (Paris) 1951 Dec;81(6):674–676. [PubMed] [Google Scholar]
  25. Deshaw M., Pirofski L. A. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals. Clin Exp Immunol. 1995 Mar;99(3):425–432. doi: 10.1111/j.1365-2249.1995.tb05568.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Devi S. J., Schneerson R., Egan W., Ulrich T. J., Bryla D., Robbins J. B., Bennett J. E. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun. 1991 Oct;59(10):3700–3707. doi: 10.1128/iai.59.10.3700-3707.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Diamond R. D., Allison A. C. Nature of the effector cells responsible for antibody-dependent cell-mediated killing of Cryptococcus neoformans. Infect Immun. 1976 Sep;14(3):716–720. doi: 10.1128/iai.14.3.716-720.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Diamond R. D., Bennett J. E. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med. 1974 Feb;80(2):176–181. doi: 10.7326/0003-4819-80-2-176. [DOI] [PubMed] [Google Scholar]
  29. Diamond R. D., May J. E., Kane M. A., Frank M. M., Bennett J. E. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol. 1974 Jun;112(6):2260–2270. [PubMed] [Google Scholar]
  30. Domer J. E., Garner R. E. Immunomodulation in response to Candida. Immunol Ser. 1989;47:293–317. [PubMed] [Google Scholar]
  31. Dromer F., Aucouturier P., Clauvel J. P., Saimot G., Yeni P. Cryptococcus neoformans antibody levels in patients with AIDS. Scand J Infect Dis. 1988;20(3):283–285. doi: 10.3109/00365548809032452. [DOI] [PubMed] [Google Scholar]
  32. Dromer F., Charreire J., Contrepois A., Carbon C., Yeni P. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun. 1987 Mar;55(3):749–752. doi: 10.1128/iai.55.3.749-752.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Dromer F., Charreire J. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J Infect Dis. 1991 May;163(5):1114–1120. doi: 10.1093/infdis/163.5.1114. [DOI] [PubMed] [Google Scholar]
  34. Dromer F., Perronne C., Barge J., Vilde J. L., Yeni P. Role of IgG and complement component C5 in the initial course of experimental cryptococcosis. Clin Exp Immunol. 1989 Dec;78(3):412–417. [PMC free article] [PubMed] [Google Scholar]
  35. Epstein J. B., Kimura L. H., Menard T. W., Truelove E. L., Pearsall N. N. Effects of specific antibodies on the interaction between the fungus Candida albicans and human oral mucosa. Arch Oral Biol. 1982;27(6):469–474. doi: 10.1016/0003-9969(82)90086-3. [DOI] [PubMed] [Google Scholar]
  36. Fischer A., Ballet J. J., Griscelli C. Specific inhibition of in vitro Candida-induced lymphocyte proliferation by polysaccharidic antigens present in the serum of patients with chronic mucocutaneous candidiasis. J Clin Invest. 1978 Nov;62(5):1005–1013. doi: 10.1172/JCI109204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. GADEBUSCH H. H. Passive immunization against Cryptococcus neoformans. Proc Soc Exp Biol Med. 1958 Jul;98(3):611–614. doi: 10.3181/00379727-98-24123. [DOI] [PubMed] [Google Scholar]
  38. GORDON M. A., LAPA E. SERUM PROTEIN ENHANCEMENT OF ANTIBIOTIC THERAPY IN CRYPTOCOCCOSIS. J Infect Dis. 1964 Oct;114:373–377. doi: 10.1093/infdis/114.4.373. [DOI] [PubMed] [Google Scholar]
  39. Gigliotti F., Hughes W. T. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest. 1988 Jun;81(6):1666–1668. doi: 10.1172/JCI113503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Goldman D. L., Lee S. C., Casadevall A. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun. 1995 Sep;63(9):3448–3453. doi: 10.1128/iai.63.9.3448-3453.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Goldman D., Lee S. C., Casadevall A. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun. 1994 Nov;62(11):4755–4761. doi: 10.1128/iai.62.11.4755-4761.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Goodner K., Horsfall F. L. THE PROTECTIVE ACTION OF TYPE I ANTIPNEUMOCOCCUS SERUM IN MICE : I. THE QUANTITATIVE ASPECTS OF THE MOUSE PROTECTION TEST. J Exp Med. 1935 Aug 31;62(3):359–374. doi: 10.1084/jem.62.3.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Goren M. B. Experimental murine cryptococcosis: effect of hyperimmunization to capsular polysaccharide. J Immunol. 1967 May;98(5):914–922. [PubMed] [Google Scholar]
  44. Graybill J. R., Hague M., Drutz D. J. Passive immunization in murine cryptococcosis. Sabouraudia. 1981 Dec;19(4):237–244. doi: 10.1080/00362178185380411. [DOI] [PubMed] [Google Scholar]
  45. Gupta S., Ellis M., Cesario T., Ruhling M., Vayuvegula B. Disseminated cryptococcal infection in a patient with hypogammaglobulinemia and normal T cell functions. Am J Med. 1987 Jan;82(1):129–131. doi: 10.1016/0002-9343(87)90388-3. [DOI] [PubMed] [Google Scholar]
  46. HURD R. C., DRAKE C. H. Candida albicans infections in actively and passively immunized animals. Mycopathol Mycol Appl. 1953 Oct 31;6(4):290–297. doi: 10.1007/BF02056710. [DOI] [PubMed] [Google Scholar]
  47. Halstead S. B. Immune enhancement of viral infection. Prog Allergy. 1982;31:301–364. [PubMed] [Google Scholar]
  48. Han Y., Cutler J. E. Antibody response that protects against disseminated candidiasis. Infect Immun. 1995 Jul;63(7):2714–2719. doi: 10.1128/iai.63.7.2714-2719.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Harmsen A. G., Chen W., Gigliotti F. Active immunity to Pneumocystis carinii reinfection in T-cell-depleted mice. Infect Immun. 1995 Jul;63(7):2391–2395. doi: 10.1128/iai.63.7.2391-2395.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Henderson D. K., Bennett J. E., Huber M. A. Long-lasting, specific immunologic unresponsiveness associated with cryptococcal meningitis. J Clin Invest. 1982 May;69(5):1185–1190. doi: 10.1172/JCI110555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Henderson D. K., Kan V. L., Bennett J. E. Tolerance to cryptococcal polysaccharide in cured cryptococcosis patients: failure of antibody secretion in vitro. Clin Exp Immunol. 1986 Sep;65(3):639–646. [PMC free article] [PubMed] [Google Scholar]
  52. Hobbs M. M., Perfect J. R., Granger D. L., Durack D. T. Opsonic activity of cerebrospinal fluid in experimental cryptococcal meningitis. Infect Immun. 1990 Jul;58(7):2115–2119. doi: 10.1128/iai.58.7.2115-2119.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Horner W. E., Helbling A., Salvaggio J. E., Lehrer S. B. Fungal allergens. Clin Microbiol Rev. 1995 Apr;8(2):161–179. doi: 10.1128/cmr.8.2.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Houpt D. C., Pfrommer G. S., Young B. J., Larson T. A., Kozel T. R. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect Immun. 1994 Jul;62(7):2857–2864. doi: 10.1128/iai.62.7.2857-2864.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Iseki M., Anzo M., Yamashita N., Matsuo N. Hyper-IgM immunodeficiency with disseminated cryptococcosis. Acta Paediatr. 1994 Jul;83(7):780–782. doi: 10.1111/j.1651-2227.1994.tb13140.x. [DOI] [PubMed] [Google Scholar]
  56. Joiner K. A., Scales R., Warren K. A., Frank M. M., Rice P. A. Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae. J Clin Invest. 1985 Nov;76(5):1765–1772. doi: 10.1172/JCI112167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Kagaya K., Shinoda T., Fukazawa Y. Murine defense mechanism against Candida albicans infection. I. Collaboration of cell-mediated and humoral immunities in protection against systemic C. albicans infection. Microbiol Immunol. 1981;25(7):647–654. doi: 10.1111/j.1348-0421.1981.tb00068.x. [DOI] [PubMed] [Google Scholar]
  58. Kaminishi H., Miyaguchi H., Tamaki T., Suenaga N., Hisamatsu M., Mihashi I., Matsumoto H., Maeda H., Hagihara Y. Degradation of humoral host defense by Candida albicans proteinase. Infect Immun. 1995 Mar;63(3):984–988. doi: 10.1128/iai.63.3.984-988.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Keller R. G., Pfrommer G. S., Kozel T. R. Occurrences, specificities, and functions of ubiquitous antibodies in human serum that are reactive with the Cryptococcus neoformans cell wall. Infect Immun. 1994 Jan;62(1):215–220. doi: 10.1128/iai.62.1.215-220.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Kirkpatrick C. H., Rich R. R., Bennett J. E. Chronic mucocutaneous candidiasis: model-building in cellular immunity. Ann Intern Med. 1971 Jun;74(6):955–978. doi: 10.7326/0003-4819-74-6-955. [DOI] [PubMed] [Google Scholar]
  61. Kong Y. M., Savage D. C., Levine H. B. Enhancement of immune responses in mice by a booster injection of Coccidioides spherules. J Immunol. 1965 Dec;95(6):1048–1056. [PubMed] [Google Scholar]
  62. Kozel T. R., Follette J. L. Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody. Infect Immun. 1981 Mar;31(3):978–984. doi: 10.1128/iai.31.3.978-984.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Kozel T. R., Gulley W. F., Cazin J., Jr Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect Immun. 1977 Dec;18(3):701–707. doi: 10.1128/iai.18.3.701-707.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Kozel T. R., McGaw T. G. Opsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages. Infect Immun. 1979 Jul;25(1):255–261. doi: 10.1128/iai.25.1.255-261.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Kuruganti U., Henderson L. A., Garner R. E., Asofsky R., Baker P. J., Domer J. E. Nonspecific and Candida-specific immune responses in mice suppressed by chronic administration of anti-mu. J Leukoc Biol. 1988 Nov;44(5):422–433. doi: 10.1002/jlb.44.5.422. [DOI] [PubMed] [Google Scholar]
  66. Kyong C. U., Virella G., Fudenberg H. H., Darby C. P. X-linked immunodeficiency with increased IgM: clinical, ethnic, and immunologic heterogeneity. Pediatr Res. 1978 Oct;12(10):1024–1026. doi: 10.1203/00006450-197810000-00015. [DOI] [PubMed] [Google Scholar]
  67. La Mantia L., Salmaggi A., Tajoli L., Cerrato D., Lamperti E., Nespolo A., Bussone G. Cryptococcal meningoencephalitis: intrathecal immunological response. J Neurol. 1986 Nov;233(6):362–366. doi: 10.1007/BF00313923. [DOI] [PubMed] [Google Scholar]
  68. Laforce F. M., Mills D. M., Iverson K., Cousins R., Everett E. D. Inhibition of leukocyte candidacidal activity by serum from patients with disseminated candidiasis. J Lab Clin Med. 1975 Oct;86(4):657–666. [PubMed] [Google Scholar]
  69. Lehner T. Serum fluorescent antibody and immunoglobulin estimations in candidosis. J Med Microbiol. 1970 Aug;3(3):475–481. doi: 10.1099/00222615-3-3-475. [DOI] [PubMed] [Google Scholar]
  70. Levitz S. M. Overview of host defenses in fungal infections. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S37–S42. doi: 10.1093/clinids/14.supplement_1.s37. [DOI] [PubMed] [Google Scholar]
  71. Louria D. B., Kaminski T. Passively-acquired immunity in experimental cryptococcosis. Sabouraudia. 1965 Jun;4(2):80–84. doi: 10.1080/00362176685190211. [DOI] [PubMed] [Google Scholar]
  72. Louria D. B., Smith J. K., Brayton R. G., Buse M. Anti-Candida factors in serum and their inhibitors. I. Clinical and laboratory observations. J Infect Dis. 1972 Feb;125(2):102–114. doi: 10.1093/infdis/125.2.102. [DOI] [PubMed] [Google Scholar]
  73. Matthews R. C., Burnie J. P., Howat D., Rowland T., Walton F. Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis. Immunology. 1991 Sep;74(1):20–24. [PMC free article] [PubMed] [Google Scholar]
  74. Matthews R. C., Burnie J. P., Tabaqchali S. Immunoblot analysis of the serological response in systemic candidosis. Lancet. 1984 Dec 22;2(8417-8418):1415–1418. doi: 10.1016/s0140-6736(84)91618-0. [DOI] [PubMed] [Google Scholar]
  75. Matthews R., Burnie J., Smith D., Clark I., Midgley J., Conolly M., Gazzard B. Candida and AIDS: evidence for protective antibody. Lancet. 1988 Jul 30;2(8605):263–266. doi: 10.1016/s0140-6736(88)92547-0. [DOI] [PubMed] [Google Scholar]
  76. Matthews R., Burnie J. The role of hsp90 in fungal infection. Immunol Today. 1992 Sep;13(9):345–348. doi: 10.1016/0167-5699(92)90169-8. [DOI] [PubMed] [Google Scholar]
  77. Matthews R., Hodgetts S., Burnie J. Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis. J Infect Dis. 1995 Jun;171(6):1668–1671. doi: 10.1093/infdis/171.6.1668. [DOI] [PubMed] [Google Scholar]
  78. Mazanec M. B., Kaetzel C. S., Lamm M. E., Fletcher D., Nedrud J. G. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6901–6905. doi: 10.1073/pnas.89.15.6901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Miller G. P., Kohl S. Antibody-dependent leukocyte killing of Cryptococcus neoformans. J Immunol. 1983 Sep;131(3):1455–1459. [PubMed] [Google Scholar]
  80. Miller M. F., Mitchell T. G., Storkus W. J., Dawson J. R. Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody. Infect Immun. 1990 Mar;58(3):639–645. doi: 10.1128/iai.58.3.639-645.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Mineo J. R., Khan I. A., Kasper L. H. Toxoplasma gondii: a monoclonal antibody that inhibits intracellular replication. Exp Parasitol. 1994 Nov;79(3):351–361. doi: 10.1006/expr.1994.1097. [DOI] [PubMed] [Google Scholar]
  82. Miyake T., Takeya K., Nomoto K., Muraoka S. Cellular elements in the resistance to candida infection in mice. I. Contribution of T lymphocytes and phagocytes at various stages of infection. Microbiol Immunol. 1977;21(12):703–725. doi: 10.1111/j.1348-0421.1977.tb00339.x. [DOI] [PubMed] [Google Scholar]
  83. Monga D. P., Kumar R., Mohapatra L. N., Malaviya A. N. Experimental cryptococcosis in normal and B-cell-deficient mice. Infect Immun. 1979 Oct;26(1):1–3. doi: 10.1128/iai.26.1.1-3.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Moser S. A., Domer J. E. Effects of cyclophosphamide on murine candidiasis. Infect Immun. 1980 Feb;27(2):376–386. doi: 10.1128/iai.27.2.376-386.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Mourad S., Friedman L. Passive immunization of mice against Candida albicans. Sabouraudia. 1968 Feb;6(2):103–105. [PubMed] [Google Scholar]
  86. Mozaffarian N., Berman J. W., Casadevall A. Immune complexes increase nitric oxide production by interferon-gamma- stimulated murine macrophage-like J774.16 cells. J Leukoc Biol. 1995 Apr;57(4):657–662. doi: 10.1002/jlb.57.4.657. [DOI] [PubMed] [Google Scholar]
  87. Mukherjee J., Casadevall A., Scharff M. D. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med. 1993 Apr 1;177(4):1105–1116. doi: 10.1084/jem.177.4.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Mukherjee J., Feldmesser M., Scharff M. D., Casadevall A. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. Antimicrob Agents Chemother. 1995 Jul;39(7):1398–1405. doi: 10.1128/aac.39.7.1398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Mukherjee J., Nussbaum G., Scharff M. D., Casadevall A. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med. 1995 Jan 1;181(1):405–409. doi: 10.1084/jem.181.1.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Mukherjee J., Pirofski L. A., Scharff M. D., Casadevall A. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3636–3640. doi: 10.1073/pnas.90.8.3636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Mukherjee J., Scharff M. D., Casadevall A. Cryptococcus neoformans infection can elicit protective antibodies in mice. Can J Microbiol. 1994 Oct;40(10):888–892. doi: 10.1139/m94-141. [DOI] [PubMed] [Google Scholar]
  92. Mukherjee J., Scharff M. D., Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun. 1992 Nov;60(11):4534–4541. doi: 10.1128/iai.60.11.4534-4541.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Mukherjee J., Scharff M. D., Casadevall A. Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains. Infect Immun. 1995 Sep;63(9):3353–3359. doi: 10.1128/iai.63.9.3353-3359.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Mukherjee J., Zuckier L. S., Scharff M. D., Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother. 1994 Mar;38(3):580–587. doi: 10.1128/aac.38.3.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Mukherjee S., Lee S. C., Casadevall A. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun. 1995 Feb;63(2):573–579. doi: 10.1128/iai.63.2.573-579.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Mukherjee S., Lee S., Mukherjee J., Scharff M. D., Casadevall A. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun. 1994 Mar;62(3):1079–1088. doi: 10.1128/iai.62.3.1079-1088.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Nabavi N., Murphy J. W. Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans. Infect Immun. 1986 Feb;51(2):556–562. doi: 10.1128/iai.51.2.556-562.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Neely A. N., Holder I. A. Effects of immunoglobulin G and low-dose amphotericin B on Candida albicans infections in burned mice. Antimicrob Agents Chemother. 1992 Mar;36(3):643–646. doi: 10.1128/aac.36.3.643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Newman S. L., Gootee L., Bucher C., Bullock W. E. Inhibition of intracellular growth of Histoplasma capsulatum yeast cells by cytokine-activated human monocytes and macrophages. Infect Immun. 1991 Feb;59(2):737–741. doi: 10.1128/iai.59.2.737-741.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Pearsall N. N., Adams B. L., Bunni R. Immunologic responses to Candida albicans. III. Effects of passive transfer of lymphoid cells or serum on murine candidiasis. J Immunol. 1978 Apr;120(4):1176–1180. [PubMed] [Google Scholar]
  101. Pirofski L., Lui R., DeShaw M., Kressel A. B., Zhong Z. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect Immun. 1995 Aug;63(8):3005–3014. doi: 10.1128/iai.63.8.3005-3014.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Polonelli L., De Bernardis F., Conti S., Boccanera M., Gerloni M., Morace G., Magliani W., Chezzi C., Cassone A. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol. 1994 Mar 15;152(6):3175–3182. [PubMed] [Google Scholar]
  103. Polonelli L., Gerloni M., Conti S., Fisicaro P., Cantelli C., Portincasa P., Almondo F., Barea P. L., Hernando F. L., Ponton J. Heat-shock mannoproteins as targets of secretory IgA in Candida albicans. J Infect Dis. 1994 Jun;169(6):1401–1405. doi: 10.1093/infdis/169.6.1401. [DOI] [PubMed] [Google Scholar]
  104. Preisler H. D., Hasenclever H. F., Levitan A. A., Henderson E. S. Serologic diagnosis of disseminated candidiasis in patients with acute leukemia. Ann Intern Med. 1969 Jan;70(1):19–30. doi: 10.7326/0003-4819-70-1-19. [DOI] [PubMed] [Google Scholar]
  105. ROWLEY D. A., HUBER M. Growth of Histoplasma capsulatum in normal, superinfected, and immunized mice. J Immunol. 1956 Jul;77(1):15–23. [PubMed] [Google Scholar]
  106. Robbins J. B., Schneerson R., Szu S. C. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis. 1995 Jun;171(6):1387–1398. doi: 10.1093/infdis/171.6.1387. [DOI] [PubMed] [Google Scholar]
  107. Roths J. B., Sidman C. L. Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice. Infect Immun. 1993 May;61(5):1641–1649. doi: 10.1128/iai.61.5.1641-1649.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Rüchel R. Cleavage of immunoglobulins by pathogenic yeasts of the genus Candida. Microbiol Sci. 1986 Oct;3(10):316–319. [PubMed] [Google Scholar]
  109. Sanford J. E., Lupan D. M., Schlageter A. M., Kozel T. R. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun. 1990 Jun;58(6):1919–1923. doi: 10.1128/iai.58.6.1919-1923.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Sarosi G. A., Parker J. D., Doto I. L., Tosh F. E. Amphotericin B in cryptococcal meningitis. Long-term results of treatment. Ann Intern Med. 1969 Dec;71(6):1079–1087. doi: 10.7326/0003-4819-71-6-1079. [DOI] [PubMed] [Google Scholar]
  111. Scheld W. M., Calderone R. A., Brodeur J. P., Sande M. A. Influence of preformed antibody on the pathogenesis of experimental Candida albicans endocarditis. Infect Immun. 1983 Jun;40(3):950–955. doi: 10.1128/iai.40.3.950-955.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Schlageter A. M., Kozel T. R. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect Immun. 1990 Jun;58(6):1914–1918. doi: 10.1128/iai.58.6.1914-1918.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Scott E. N., Muchmore H. G., Felton F. G. Enzyme-linked immunosorbent assays in murine cryptococcosis. Sabouraudia. 1981 Dec;19(4):257–265. doi: 10.1080/00362178185380431. [DOI] [PubMed] [Google Scholar]
  114. Slack J., Der-Balian G. P., Nahm M., Davie J. M. Subclass restriction of murine antibodies. II. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency. J Exp Med. 1980 Apr 1;151(4):853–862. doi: 10.1084/jem.151.4.853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Solomkin J. S., Mills E. L., Giebink G. S., Nelson R. D., Simmons R. L., Quie P. G. Phagocytosis of Candida albicans by human leukocytes: opsonic requirements. J Infect Dis. 1978 Jan;137(1):30–37. doi: 10.1093/infdis/137.1.30. [DOI] [PubMed] [Google Scholar]
  116. Stratta R. J., Shaefer M. S., Cushing K. A., Markin R. S., Reed E. C., Langnas A. N., Pillen T. J., Shaw B. W., Jr A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg. 1992 Jan;127(1):55–64. doi: 10.1001/archsurg.1992.01420010065009. [DOI] [PubMed] [Google Scholar]
  117. Sundstrom P., Jensen J., Balish E. Humoral and cellular immune responses to enolase after alimentary tract colonization or intravenous immunization with Candida albicans. J Infect Dis. 1994 Aug;170(2):390–395. doi: 10.1093/infdis/170.2.390. [DOI] [PubMed] [Google Scholar]
  118. Tabone M. D., Leverger G., Landman J., Aznar C., Boccon-Gibod L., Lasfargues G. Disseminated lymphonodular cryptococcosis in a child with X-linked hyper-IgM immunodeficiency. Pediatr Infect Dis J. 1994 Jan;13(1):77–79. doi: 10.1097/00006454-199401000-00020. [DOI] [PubMed] [Google Scholar]
  119. Takeya K., Nomoto K., Matsumoto T., Miyake T., Himeno K. Chronic mucocutaneous candidiasis accompanied by enhanced antibody production. Clin Exp Immunol. 1976 Sep;25(3):497–500. [PMC free article] [PubMed] [Google Scholar]
  120. Umazume M., Ueta E., Osaki T. Reduced inhibition of Candida albicans adhesion by saliva from patients receiving oral cancer therapy. J Clin Microbiol. 1995 Feb;33(2):432–439. doi: 10.1128/jcm.33.2.432-439.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Vudhichamnong K., Walker D. M., Ryley H. C. The effect of secretory immunoglobulin A on the in-vitro adherence of the yeast Candida albicans to human oral epithelial cells. Arch Oral Biol. 1982;27(8):617–621. doi: 10.1016/0003-9969(82)90184-4. [DOI] [PubMed] [Google Scholar]
  122. Walker S. M., Urbaniak S. J. A serum-dependent defect of neutrophil function in chronic mucocutaneous candidiasis. J Clin Pathol. 1980 Apr;33(4):370–372. doi: 10.1136/jcp.33.4.370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Witkin S. S. Inhibition of Candida-induced lymphocyte proliferation by antibody to Candida albicans. Obstet Gynecol. 1986 Nov;68(5):696–699. [PubMed] [Google Scholar]
  124. Yuan R., Casadevall A., Spira G., Scharff M. D. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol. 1995 Feb 15;154(4):1810–1816. [PubMed] [Google Scholar]
  125. Zebedee S. L., Koduri R. K., Mukherjee J., Mukherjee S., Lee S., Sauer D. F., Scharff M. D., Casadevall A. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob Agents Chemother. 1994 Jul;38(7):1507–1514. doi: 10.1128/aac.38.7.1507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. al-Doory Y. An immune factor in baboon anti-candida serum. Sabouraudia. 1970 May;8(1):41–47. doi: 10.1080/00362177085190621. [DOI] [PubMed] [Google Scholar]
  127. de Repentigny L., Petitbois S., Boushira M., Michaliszyn E., Sénéchal S., Gendron N., Montplaisir S. Acquired immunity in experimental murine aspergillosis is mediated by macrophages. Infect Immun. 1993 Sep;61(9):3791–3802. doi: 10.1128/iai.61.9.3791-3802.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES